JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Guardant Health Inc

Fermé

SecteurSoins de santé

114.32 0.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

112.28

Max

115.88

Chiffres clés

By Trading Economics

Revenu

7.2M

-93M

Ventes

33M

265M

Marge bénéficiaire

-34.965

Employés

1,999

EBITDA

6.6M

-82M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+12.53% upside

Dividendes

By Dow Jones

Prochains Résultats

19 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

5.9B

15B

Ouverture précédente

113.55

Clôture précédente

114.32

Sentiment de l'Actualité

By Acuity

50%

50%

147 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Guardant Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 févr. 2026, 23:52 UTC

Acquisitions, Fusions, Rachats

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 févr. 2026, 23:52 UTC

Acquisitions, Fusions, Rachats

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 févr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 févr. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 févr. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 févr. 2026, 23:23 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 févr. 2026, 22:57 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 févr. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 févr. 2026, 21:51 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 févr. 2026, 21:49 UTC

Résultats

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 févr. 2026, 21:39 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:36 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 févr. 2026, 21:34 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:28 UTC

Acquisitions, Fusions, Rachats

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 févr. 2026, 21:23 UTC

Résultats

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 févr. 2026, 21:19 UTC

Résultats

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 févr. 2026, 21:17 UTC

Résultats

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 févr. 2026, 21:17 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:10 UTC

Résultats

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 févr. 2026, 21:08 UTC

Résultats

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 févr. 2026, 21:07 UTC

Résultats

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Net $608.7M >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Rev $1.41B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 févr. 2026, 21:05 UTC

Résultats

Palantir Technologies 4Q EPS 24c >PLTR

2 févr. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparaison

Variation de prix

Guardant Health Inc prévision

Objectif de Prix

By TipRanks

12.53% hausse

Prévisions sur 12 Mois

Moyen 128.33 USD  12.53%

Haut 175 USD

Bas 105 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

19 ratings

18

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

38.86 / 47.41Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

147 / 352Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat